This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Cornell University, University of Utah Research Foundation. Active years: 2025.
Company Filing History:


Years Active: 2025
Title: Christopher Butson: Innovator in Central Thalamus Activation Methods
Introduction
Christopher Butson is a notable inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of neuroscience, particularly in the methods for selective activation of central thalamus fibers. His innovative approach has the potential to enhance therapeutic interventions for various neurological conditions.
Latest Patents
Christopher Butson holds a patent titled "Methods for selective activation of central thalamus fibers in a subject and systems therefor." This patent describes a method that involves positioning one or more electrodes with contacts in the subject's central thalamus fibers. An electrical stimulus is then applied to these electrodes to selectively activate the central thalamus fibers. The method aims to maximize activation of the central lateral nucleus and medial dorsal tegmental tract fiber pathways while minimizing activation of the central median parafascicularis fiber pathway. Additionally, the patent includes methods, devices, and computer-readable media for surgical planning involving this selective activation.
Career Highlights
Throughout his career, Christopher Butson has worked with esteemed institutions such as Cornell University and the University of Utah Research Foundation. His work has focused on advancing the understanding and treatment of neurological disorders through innovative technologies.
Collaborations
Some of his notable coworkers include Nicholas Schiff and Jonathan Baker. Their collaborative efforts have contributed to the development of groundbreaking techniques in the field of neuroscience.
Conclusion
Christopher Butson's work in the selective activation of central thalamus fibers represents a significant advancement in neuroscience. His innovative methods and collaborations with leading researchers continue to pave the way for future developments in neurological therapies.